{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Terman SW"],"funding":["NCATS NIH HHS","NIA NIH HHS","NIH Office of the Director","NIMHD NIH HHS","NINDS NIH HHS"],"pagination":["2778-2789"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8563423"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(11)"],"pubmed_abstract":["<h4>Objective</h4>This study was undertaken to characterize trajectories of antiseizure medication (ASM) adherence in adults with newly treated epilepsy and to determine predictors of trajectories.<h4>Methods</h4>This was a retrospective cohort study using Medicare. We included beneficiaries with newly treated epilepsy (one or more ASM and none in the preceding 2 years, plus International Classification of Diseases codes) in 2010-2013. We calculated the proportion of days covered (proportion of total days with any ASM pill supply) for 8 quarters or until death. Group-based trajectory models characterized and determined predictors of trajectories.<h4>Results</h4>We included 24 923 beneficiaries. Models identified four groups: early adherent (60%), early nonadherent (18%), late adherent (11%), and late nonadherent (11%). Numerous predictors were associated with being in the early nonadherent versus early adherent group: non-White race (e.g., Black, odds ratio [OR] = 1.7, 95% confidence interval [CI] = 1.5-1.8), region (e.g., South vs. Northeast: OR = 1.2, 95% CI = 1.1-1.4), and once daily initial medication (OR = 1.1, 95% CI = 1.0-1.3). Predictors associated with decreased odds of being in the early nonadherent group included older age (OR = .9 per decade, 95% CI = .9-.9), female sex (OR = .9, 95% CI = .8-1.0), full Medicaid eligibility (OR = .6, 95% CI = .4-.8), neurologist visit (OR = .6, 95% CI = .6-.7), and initial older generation ASM (OR = .6, 95% CI = .6-.7).<h4>Significance</h4>We identified four ASM adherence trajectories in individuals with newly treated epilepsy. Whereas risk factors for early nonadherence such as race or geographic region are nonmodifiable, our work highlighted a modifiable risk factor for early nonadherence: lacking a neurologist. These data may guide future interventions aimed at improving ASM adherence, in terms of both timing and target populations."],"journal":["Epilepsia"],"pubmed_title":["Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy."],"pmcid":["PMC8563423"],"funding_grant_id":["UL1 TR002240","K76 AG059929","R25 NS065723","R01 MD008879","T32 NS007222","R25NS065723"],"pubmed_authors":["Terman SW","Burke JF","Kerr WT","Marcum ZA","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy.","description":"<h4>Objective</h4>This study was undertaken to characterize trajectories of antiseizure medication (ASM) adherence in adults with newly treated epilepsy and to determine predictors of trajectories.<h4>Methods</h4>This was a retrospective cohort study using Medicare. We included beneficiaries with newly treated epilepsy (one or more ASM and none in the preceding 2 years, plus International Classification of Diseases codes) in 2010-2013. We calculated the proportion of days covered (proportion of total days with any ASM pill supply) for 8 quarters or until death. Group-based trajectory models characterized and determined predictors of trajectories.<h4>Results</h4>We included 24 923 beneficiaries. Models identified four groups: early adherent (60%), early nonadherent (18%), late adherent (11%), and late nonadherent (11%). Numerous predictors were associated with being in the early nonadherent versus early adherent group: non-White race (e.g., Black, odds ratio [OR] = 1.7, 95% confidence interval [CI] = 1.5-1.8), region (e.g., South vs. Northeast: OR = 1.2, 95% CI = 1.1-1.4), and once daily initial medication (OR = 1.1, 95% CI = 1.0-1.3). Predictors associated with decreased odds of being in the early nonadherent group included older age (OR = .9 per decade, 95% CI = .9-.9), female sex (OR = .9, 95% CI = .8-1.0), full Medicaid eligibility (OR = .6, 95% CI = .4-.8), neurologist visit (OR = .6, 95% CI = .6-.7), and initial older generation ASM (OR = .6, 95% CI = .6-.7).<h4>Significance</h4>We identified four ASM adherence trajectories in individuals with newly treated epilepsy. Whereas risk factors for early nonadherence such as race or geographic region are nonmodifiable, our work highlighted a modifiable risk factor for early nonadherence: lacking a neurologist. These data may guide future interventions aimed at improving ASM adherence, in terms of both timing and target populations.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-03T22:45:19.1Z","creation":"2025-02-19T01:30:50.761Z"},"accession":"S-EPMC8563423","cross_references":{"pubmed":["34462911"],"doi":["10.1111/epi.17051"]}}